Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2025—Qiagen announced a series of product and partnership updates, including a new set of QIAseq panels for comprehensive genomic profiling, a QIAcuity digital PCR kit and assays for cell and gene therapy quality control, and a free, limited version of the Human Somatic Mutation Database from the Qiagen Digital Insights bioinformatics business.
August 2025—Precision Epigenomics presented validation data for its flagship multicancer early detection (MCED) test, Episeek, at the 2025 ASCO annual meeting in Chicago, May 30–June 3. The data demonstrated that the blood-based test is capable of identifying more than 60 cancer types with a 99.5 percent specificity rate and a turnaround time of two to three days. The test was validated on 281 cancer-positive plasma samples across all four stages and 201 samples from healthy people over 40 years old. It showed a 45 percent sensitivity for stage I/II cancers and a 74 percent sensitivity for stage IV cancers, with positive and negative predictive values of 64.9 percent and 99.5 percent, respectively.
August 2025—CytoChip showcased its flagship product, CitoCBC, a cartridge-based CBC analyzer, at the Association for Diagnostics and Laboratory Medicine annual meeting, July 27–31, in Chicago. CitoCBC delivers rapid CBC results with a five-part white blood cell differential from a cartridge-based system and requires only monthly quality control.
August 2025—EntroGen announced that its CRCdx RAS mutation detection kit has received national coverage from the Centers for Medicare and Medicaid Services. CRCdx is an FDA-approved, real-time PCR-based companion diagnostic for use in identifying patients eligible for treatment with Vectibix (panitumumab), based on the absence of KRAS and NRAS mutations.
July 2025—Bio-Rad Laboratories will present an array of clinical diagnostic-related offerings at this year’s Association for Diagnostics and Laboratory Medicine Clinical Lab Expo in Chicago, July 27–31. An industry workshop titled “From Waste to Wow: Optimizing Your Quality Control Workflow” is designed to provide attendees with strategies to streamline QC management across multihospital systems for systemwide efficiency, reduce waste streams in clinical chemistry, and recognize patient-based real-time QC to improve lab QC processes.
July 2025—StaffReady has released a mobile app for its StaffReady Scheduling. The app is available on Apple and Android devices and offers StaffReady’s Calendar feature for users to easily view a schedule, request PTO, or make detailed shift requests, such as giveaways, trades, or bids. In addition, the company offers a weekly educational newsletter on its new website. It provides content specific to ancillary markets such as laboratories, pharmacies, and physical therapy/rehab departments and focuses on trends that affect workforce management in health care.
July 2025—The Food and Drug Administration has approved the de novo application for Randox Laboratories’ first companion diagnostic, the Randox ConcizuTrace ELISA. The test, developed in collaboration with Novo Nordisk, is intended for the quantitative measurement of concizumab-mtci concentration in human 3.2 percent citrated plasma samples from patients with hemophilia A and B four weeks after the initiation of treatment. The measurement of the concentration is used for dose adjustment decision in accordance with the drug label.
July 2025—Ibex Medical Analytics reports that a study conducted at Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution, significantly improves accuracy and efficiency in evaluating breast pathology cases (Tahir M, et al. Clin Breast Cancer. Published online March 26, 2025). The study analyzed 104 real-world breast biopsies, including invasive and microinvasive carcinomas, ductal carcinoma in situ, atypical lobular hyperplasia, and other benign lesions. Three breast pathologists independently reviewed each case digitally, with and without the support of Ibex Breast. Results demonstrated that when using AI, diagnostic accuracy improved from 97.1 percent to 100 percent, with previously missed precancerous lesions, such as lobular neoplasia and microcalcifications, correctly identified.
July 2025—BD announced the worldwide commercial launch of its FacsDiscover A8 cell analyzer. It features BD SpectralFX technology, which maximizes the number of colors that can be used in flow cytometry; BD CellView image technology, which enables high-speed fluorescent and label-free imaging of single cells; and intuitive software workflows that allow for effective management of large data sets. The analyzer pairs with BD FacsDiscover cell sorters and BD reagents.
July 2025—Diasorin has received 510(k) clearance from the FDA for its Liaison Plex Gram-positive blood culture assay. The assay detects 17 targets (13 Gram-positive bacteria and four relevant resistance gene targets) in less than two hours and features Diasorin’s proprietary NanoGrid technology, which allows the detection of nucleic acids without the need for conventional amplification reactions.
